Ilana Fogelman Email

Co-Founder and Senior Advisor for Medical Innovation . C2N Diagnostics

St Louis, MO

Location

i********@c2n.com

Primary Email

LinkedIn

Current Roles

Employees:
96
Revenue:
$13.5M
About
C₂N Diagnostics' vision is to bring Clarity Through Innovation™. It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. Diagnostic efforts revolve around bringing accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring. Its lead commercial product, the PrecivityAD™ blood test, is a mass spectrometry-based test performed in C₂N's CLIA-certified lab that measures in blood multiple analytes including Aβ42, Aβ40, and apolipoprotein E isoforms. While the test by itself cannot diagnose Alzheimer's disease — which is a clinical diagnosis made by a health care provider — the test is an important new tool for physicians to aid in the evaluation process. PrecivityAD™, which can only be ordered through a health care provider, predicts brain amyloid plaques as determined by PET scan results and in 2019 it received a Breakthrough Device Designation from the U.S. Food and Drug Administration. The PrecivityAD™ blood test also has achieved the CE Mark from the European Union. For more information visit www.C2N.com.
C2N Diagnostics Address
4340 Duncan Avenue
St Louis, MO
United States
C2N Diagnostics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.